* If you want to update the article please login/register
Abstract The effectiveness of 177Lu-DOTATATE in patients of neuroendocrine tumors with widespread skeletal metastases is limited by its relatively low response rates and a serious concern for hematotoxicity. Targeted therapy with 225Ac-DOTATATE can be highly effective in these situations. Consequently, the first-line use of 225Ac-DOTATATE provides a new path for metastatic NETs with a high incidence of bone disease burden.
Source link: https://europepmc.org/article/MED/34284478
Hypoglycemia in the context of multiple pancreatic tumors is extremely unusual in the symptom of severe hypoglycemia. There have been no autopsy cases of colorectal carcinoma in NICTH, with serum high molecular weight and tumoral IGF-II. We present the case of a 46-year-old woman with advanced sigmoid colon cancer and liver metastases. Both metastatic carcinoma of the liver and primary colonic adenocarcinoma were positive for IGF-II. Immunohistochemistry revealed that both metastatic carcinoma of the liver and primary colonic adenocarcinoma were positive for IGF-II. Neuroendocrine differences in liver metastases identified by an autopsy may have contributed to tumor formation, which may have exacerbated the symptoms.
Source link: https://europepmc.org/article/MED/35089636
Background: It has been unclear if primary tumor resection will give patients with metastatic small intestine neuroendocrine tumors a benefit. To answer this question, we conducted a retrospective cohort study to see the effect of PTR on the longevity of patients with metastatic SI-NETs. To determine the relationship between PTR and treatment results, a Cox proportional hazard regression model was used. PTR significantly extended the survival of metastatic SI-NETs patients, according to a Prism-based survival study. There was no significant difference between the PTR group and the non-PTR group after PSM, and cancer-specific survival and long-term survivors. Conclusion Our report shows that OS and CSS are similar between the PTR group and the non-PTR group. Patients' outcomes are still to be determined by prospective randomized controlled trials to determine the effect of PTR on patients in the future.
Source link: https://europepmc.org/article/MED/34991432
DOTA-TATE was used in organs and tumor lesions in NET patients treated with indigenously produced "direct-route" [ 177 Lu]Lu-labeled DOTA-TATE and comparison to others treated with no-carrier-added DOTA-TATE (177 Lu) Lustig-labeled DOTA-TATE [ 177 Lu] Lu | 177 Lu] DOTA-TATE [ 177 Lu]Lu-TATE t absorbed doses in organs in organs in kidney and tumor lesions in versus those and tumor lesions [ absorbed doses and tumor lesions [ t n [ t t's in organs and tumor lesions absorbed DOTA-TATE and comparatived tATE [ t]Lu-TATE TE Using OLINDA 2. 1. 1 software, the absorbed doses for normal organs and tumor lesions were determined. The mean absorbed organ doses in Gy/GBq received by normal organs were as follows: kidneys 0. 64 0. 21, liver 0. 10 0. 02, spleen 0. 07 0. 06, and whole-body 0. 06 0. 02. In a total of 410 tumor lesions, Tumor dosimetry was performed, the average absorbed dose to the tumor lesions was 4. 79 4. 23 Gy/GBq. With no-carrier-added [177 Lu]Lu-DOTA-TATE's mean absorbed organ doses in Gy/GBq obtained by normal organs were as follows: kidneys 0. 76 0. 05, liver 0. 10 0. 05, spleen 1. 14 0. 05, heart wall 0. 07 0. 02, and tumor dose 5. 77 5. 74, and tumor dose 5. 87 5. 74. Conclusions: There was no statistically significant difference in the dosimetry results of patients treated with no-carrier-added DOTA-TATE and the dosimetry results of patients treated with [ 177 Lu]Lu-labeled DOTA-TATE and the dosimetry results of patients treated with [ 177 Lu]Lu-labeled DOTA-TATE and the dosimetry results of patients treated with [ 177 Lu]Lu-labeled.
Source link: https://europepmc.org/article/MED/34910891
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions